Project Launched by VTT Develops Computer Models for Predicting Dietary Effects on Health

VTT is launching an extensive EU project called ETHERPATHS, studying the effects of dietary effects mediated by gut microbiota on lipid metabolism. The aim is to accelerate the development of health-promoting foods. The project develops computer assisted models with which food companies and research institutions, for instance, will be able to predict the effects of foods in the body.

The ETHERPATHS project focuses on the balance of lipid metabolism in the body, the effects of foods in tissues and the role of gut microbiota in these processes. Lipid metabolism disorders are associated with several common health care problems, such as ageing, diabetes and cardiovascular diseases. The balance can be influenced by dietary means. The risk of chronic diseases decreases with a diet containing particularly omega-3 fatty acids and foods that contain fibres and phenol. Therefore, fatty fish, berries, fruits and vegetables may be favourable foods in terms of lipid metabolism balance. The body’s own phospholipids are assumed to mediate the health-promoting effects, but their mechanisms of action are still unknown.

The project develops computer-assisted models that emulate the changes in lipid metabolism brought about by eating fish and vegetable oil, berries, fruits and vegetables. The use of models makes it easier to combine data from animal studies and cell-level data in the interpretation of research data from clinical trials, thus promoting research in the health effects of foods and development of foodstuffs. The results of the project and the tools developed in it will in time also be available to in addition to food companies to companies and research institutions that develop diagnostics of health and disease.

The coordinator of the ETHERPATHS project is VTT's Research Professor Matej Oresic. The total project budget for 2009–2012 is EUR 8 million, of which VTT's share is EUR 2.5 million. The project involves a total of 10 European research institutions and companies.

The project partners are: VTT (Finland), University of Barcelona (Spain), University of Gothenburg (Sweden), University of Cambridge (United Kingdom), Institute for Systems Biology SPb (Russia), Federico II University of Naples (Italy), Noray Bioinformatics S.L.U. (Spain), BioMotif AB (Sweden), Advion Biosciences, Ltd. (United Kingdom) and Nestle Research Center (Switzerland). The project is part of the EU FP7 Cooperation Work Programme: Food, agriculture and fisheries, and biotechnology programme (KBBE-2007-2-2-08).

About VTT Technical Research Centre of Finland
VTT Technical Research Centre of Finland is the biggest contract research organization in Northern Europe. VTT provides high-end technology solutions and innovation services. From its wide knowledge base, VTT can combine different technologies, create new innovations and a substantial range of world-class technologies and applied research services, thus improving its clients' competitiveness and competence. Through its international scientific and technology network, VTT can produce information, upgrade technology knowledge and create business intelligence and value added to its stakeholders. For more information, visit http://www.vtt.fi.

Most Popular Now

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...